anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a novel crosslinked DNA insoluble in water and a method of using the same as a material for environmental cleanup.  &lt;P&gt;SOLUTION: When an aqueous solution of a water-soluble DNA (for example, DNA derived from the spermary of a salmon) or its aqueous film on a support or a thin aqueous film liquid of a water-soluble DNA on a support is irradiated with an ultraviolet ray having a wavelength in the range of 250-270 nm, the DNA on the support is changed into an immobilized, water-insoluble, and crosslinked product. In the same manner, for example, by irradiating an aqueous solution of a water-soluble DNA, in which a cellulose fiber nonwoven fabric is immersed, with ultraviolet rays having a wavelength in the range of 250-270 nm, a cellulose fiber nonwoven fabric coated with a water insoluble crosslinked polymer of the DNA is formed. This crosslinked product adsorbs an intercalating agent into DNA or an endocrine-disrupting chemical in water even at a very low concentration in an extremely high yield. The crosslinked product similarly adsorbs a toxic metal such as an Hg ion relative to water in an immobilizing manner. Accordingly, this crosslinked product is useful as an environmentally purifying material.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
PURPOSE:To provide an antimyodystrophic agent containing 24,25-dihydrocholecalciferol as an active component, effective to myodystrophia and having high safety. CONSTITUTION:The objective antimyodystrophic agent contains 24,25-dihydroxy cholecalciferol (abbreviated as the present substance) of e.g. formula I . The present substance has been already known to have antihypercalcemic and antitumor activities, etc., however, it has been newly found that the compound also has antimyodystrophic activity. The active component is preferably 24R,25-(OH)2- D3 of formula II. Dose: preferably 0.5-1X10&lt;4&gt;mug/day by oral administration.
A polymer having a molecular weight less than 6000 which is soluble in water at basic pH values and having the formula &lt;FORM:1002455/C3/1&gt; where R is a C2- 4 alkylene radical which may contain as substituent a C1- 4 alkyl, carboxyl or carbalkoxy group; R1 is H or a C1- 4 alkyl, and R11 and R111 are R1, aryl, aryloxy or a C1- 4 alkoxy, and n is 1-24 is prepared by reacting a copolymer containing &lt;FORM:1002455/C3/2&gt; with an aminothiol of formula HS-R-NHR1, where R and R1 are as before.  The polymer may be produced by copolymerizing maleic anhydride with styrene or ethylene and then reacting the copolymer with b -mercapto-ethylamine or cysteine. The thiolated polymer, e.g. 1-20%, may be compounded with urea, ammonia, and water.ALSO:Keratinic fibres are impregnated with a solution e.g. 1-20%, of a polymer of molecular weight less than 6,000 which is soluble in water at baric pH values and which has the formula &lt;FORM:1002455/D1-D2/1&gt; where R is a C2-4 alkylene which may be substituted, R1 is H or a C1-4 alkyl and R11 and R111 are R1, aryl, arylotz or C1-4 alkoxy and n is 1-24. The solution may also contain urea and ammonia.  The fibre may be wool or natural hair on the human head and may be constrained during treatment to a desired configuration.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a base for percutaneous absorption preparation having excellent percutaneous absorption of medicine and a skin patch preparation, in detail a base for percutaneous absorption preparation and a skin patch preparation in which the main component of the base and the kind of the medicine are widely selected.  &lt;P&gt;SOLUTION: The base for percutaneous absorption preparation comprises a chain alcohol that is a branched alcohol and has 10-30 total carbon atoms and 5-20 carbons of the longest straight chain. The amount of the chain alcohol contained in the base for the percutaneous absorption preparation is 15-50 wt.%. The chain alcohol is preferably a monofunctional primary chain alcohol, concretely isostearyl alcohol, hexyldecanol, octyldodecanol, etc., may be cited as the chain alcohol. Preferably an adhesive is used as the main component of the base for the percutaneous absorption preparation and the layer of the base is formed on one side of a sheetlike substrate to form the skin patch preparation.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an excellent enteric preparation which does not need water, when orally taken, can also easily be taken by a swallowing-difficult patient, and has improved compliance.  &lt;P&gt;SOLUTION: This enteric preparation is characterized by comprising a medicine, pectin and water. The preparation is not dissolved under an acidic condition having a pH 1.2 to 3.5 which is the pH of gastric juice, is quickly dissolved at a pH 6 to 8 in large intestine, and can sufficiently correspond to demands as the enteric preparation. The preparation can be obtained by compounding water in the preparation. The preparation can be prepared in a dosage form such as a liquid preparation, a jelly preparation, an ointment-like preparation or a cream preparation, does not need water when taken, can also easily be taken by a swallowing-difficult patient, and has improved compliance.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an emergency transmission system that enables a paramedic to quickly and precisely report a patient&#39;s symptoms by means of an electronic pen when performing an emergency aid procedure according to a doctor&#39;s instructions.  &lt;P&gt;SOLUTION: In the emergency transmission system 100, the paramedic writes a patient&#39;s symptoms on a symptom fill-out form 3 using the electronic pen 10 inside an emergency vehicle or the like. Then the electronic pen 10 obtains written information corresponding to details written on the symptom fill-out form 3 and sends this information to a server 6 via a mobile terminal 5. Next, based on the written information obtained, the server 6 generates the image data of a stroke written on the symptom fill-out form 3 with the electronic pen 10, and saves the data. Further, the server 6 sends the image data of the stroke to a hospital terminal 7. Based on the image data obtained from the server 6, the hospital terminal 7 displays the image of the stroke on a display or the like.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
Novel 1-(2-phenyl-2-hydroxyethylamino)-3-phenoxypropan-2-ols of formula I are obtained by reacting a corresponding epoxide or chlorohydrin with a phenoxypropanolamine. During the reaction, the groups R1, R2, R3, R5 and R6 can be protected by a hydrogenolytically cleavable group. Protective groups present are cleaved after the reaction. The symbols in formula I have the meaning given in the patent claim. The compounds of formula I have a cardiovascular action and furthermore have a vascular-dilating, antihypertensive and antiarrhythmic action. &lt;IMAGE&gt;
Process for obtaining certain ureylenes- [(substituted or unsubstituted-phenylenecarbonyl) bis- (substituted-naphthalemonosulfonic acids)] and salts thereof, useful as inhibitors of connective tissue destruction. Abnormal destruction of the connective tissue by collagenase and/or neutral proteases causes tissue damage and/or tissue dysfunction. Under these conditions, an inhibitor of connective tissue destruction that will act directly or indirectly, to avoid, delay or reverse tissue damage and/or collagenous diseases would be useful. The term &#34;connective tissue&#34; refers to a matrix of at least 3 protein molecules, collagen, proteoglycan and elastin. These molecules play an important role in the structural integrity of normal tissues. (Machine-translation by Google Translate, not legally binding)
FIELD: biotechnology, veterinary science. SUBSTANCE: strain of bacterium Pseudomonas aeruginosa 476 2  is deposited in collection of strains that are pathogens of diseases in fur wild animals of museum of bacterial and viral cultures (NIIPZK) named for V .A. Afanasiev and has registration number 476 2 . Strain relates to serovariant 02/05. Strain is cultured in Marten&#39;s broth or synthetic medium at 32 C for 18-20 h at constant shaking. After control of grown culture for toxicogenicity and proteolytic activity bacterial mass is separated and inactivated. Then aluminum hydroxide is added as an adjuvant and packaged. Invention ensures to prevent the concealed loss in fur wild animals reproduction in farms with pyocyanic infection being independently of serological pattern of pathogen. EFFECT: strain indicated above, enhanced effectiveness of vaccine. 3 ex
&lt;P&gt;PROBLEM TO BE SOLVED: To improve operability and convenience of a medical image system.  &lt;P&gt;SOLUTION: In the medical image system 1, a CPU 11 extracts a patient&#39;s disease site to be an object from a plurality of sites corresponding to a designated part in a medical information database when one part on a site designating screen is designated, and displays a listing screen of the disease site on a display part 13. When the disease site is selected on the listing screen of the disease site, the CPU 11 displays the listing screen of a photographing name of a detailed screen regarding the disease site on the part 13. The photographing name photographed with respect to the disease site and a representative image are displayed on the listing screen of the photographing name. When one of the photographing names is selected, the CPU 11 displays the screen according to the photographing name on the part 13, and when an image index is selected on the screen according to the photographing name, the CPU 11 displays the selected medical image on the part 13.  &lt;P&gt;COPYRIGHT: (C)2003,JPO
This invention is a new extraction process by adding solvent into Friuts Arctium lappa L. (FAL) and reflux extraction by heat. First, Fructus Arctii were prepared by different solvents and method, we could obtain four crude extracts. This experiment was aimed to investigate the relaxation effect of these crude extracts on corpus cavernosal smooth muscle (CCSM) which isolation of rabbit relaxation. The most potent one among these crude extracts was found to fraction partition by different solvents and five fractional extracts were prepared. Fractional extracts were 100% relaxation ( p &amp;lt; 0.001) on CCSM at 100 &amp;mgr; g/ml. In conclusion, the contraction of CCSM was actually inhibited by FAL and we suggested that FAL might be helpful to improve erectile dysfunction.
The present invention relates to a medicine for treating alopecia areata, which is a traditional Chinese medicine preparation of oral administration. The present invention is characterized in that dose for one day is made from the following traditional Chinese medicine raw material of 12 grams of pinellia tubers, 8 grams of fleece-flower roots, 8 grams of arborvitae seeds, 10 grams of Chicken&#39;s gizzard membranes (fried and ground), 7 grams of prepared rhizomes of rehmannia, 10 grams of tuckahoe, 10 grams of pilose asiabell roots, 10 grams of astragalus roots and 8 grams of Chinese caterpillar fungi. The present invention has the efficiency of liver and kidney nourishing, qi and blood nourishing, meridian dredging, blood circulation promotion, wind dispelling, itch arrest, hair solidification and hair restoration without side effect. The present invention has the advantages of convenient administration and rapid effect taking. New hair grows out at alopecia areata points in one month, the alopecia areata is generally cured after two to five treatment courses, and the therapeutic effect is significant. The clinic tracking of 200 people shows that he therapeutic rate is 95%. The present invention is suitable for various alopecia and alopecia areata pathological symptoms.
The present disclosure relates to global medical data analysis methods, systems, and computer program products for analyzing, classifying, and matching large amounts of medical information from many sources across different regions. The global medical data analysis system includes a master medical server with an intelligent medical engine communicatively coupled to a central database, a secure electronic medical records database, and also communicatively coupled to hospitals, clinics, and other medical sources over a network. The intelligent medical engine receives expensive medical records, potentially from different countries, regions, and continents. Electronic medical records originate in hospitals, clinics, and other medical sources, which are fed to intelligent medical engines for mass analysis and correlation of medical records for patients worldwide. The analysis begins with grouping (classifying) the medical records down into multi-level subgroups based on patient clinical parameters, disease templates, treatment, and outcomes. When a new patient enters the system, the patient&#39;s parameters and disease template are matched to the closest subgroup to suggest a treatment with potentially beneficial consequences.
PURPOSE:To efficiently separate and recover a high protein fraction and a high dietary fiber fraction from wheat bran by grinding the wheat bran into a bran powder having a specified particle size, removing the coarse powder and subsequently classifying the residual powder into fractions, respectively, having a specified particle size. CONSTITUTION:I. Wheat bran is ground into a powdery bran of wheat containing &gt;=60wt.% powder having a particle size within a range of 10-300mum [process (a)]. II. From the powdery bran of wheat prepared by the process (a), coarse powder having &gt;=300+ or -25mum particle size is separated and classified as (A) fraction [process (b)]. III. From the residual powder from which the coarse powder [fraction (A) is removed in the process (b), fine powder having &lt;=30mum particle size is separated [process (c)], as necessary, and classified as (D) fraction. IV. The residual powder after above-mentioned processes (b) and (d) is finally classified into a fraction [a high dietary fiber fraction: (B) fraction] having &gt;100+ or -25mum particle size and the other fraction [high protein fraction: (C) fraction] having &lt;=100+ or -25mum particle size.
PURPOSE:To obtain the titled vaccine, by heat-treating an aqueous solution of human plasma protein containing a B-type hepatitis surface antigen (HBsAg), removing a plasma component and a B-type hepatitis infectious component from it by a specific purification, subjecting it to deactivation treatment of infection. CONSTITUTION:An aqueous solution of human plasma protein containing HBsAg is heat-treated at 50-70 deg.C, precipitated protein is removed by 10-20wt% saturation of ammonium sulfate, precipitated protein by 40-50wt% saturation of ammonium sulfate is collected, and brought into contact with a colloidal silicate. HBsAg is adsorbed on the salt, adsorbed HBsAg is eluted with a buffer solution, and the elute is adjusted to approximately neutrality. Polyethylene glycol is added to the elute, B-type hepatitis virus (HBV) and an immune complex are precipitated and removed, the above-mentioned glycol is added to a supernatant liquid, and HBsAg is precipitated and collected. It is subjected to gel filtration and ultracentrifugation, to recover HBsAg having 18-24mm. particle diameters and 1.18-1.22g/cm&lt;3&gt; specific gravity. It is further deactivated, dialyzed, lyophilized, to give a vaccine for preventing infection of B-type hepatitis.
PURPOSE:To prepare inorganic oxide particles having improved various characteristics, by adding a solution containing a specific organosilicon compound and an organometallic compound to an alkaline solvent, and hydrolyzing both compounds. CONSTITUTION:A hydrolyzable organosilicon compound, e.g. an alkoxysilane, and a hydrolyzable organic compound of a metal selected from GroupIin the periodic table, e.g. K, Li or Na, are added to an alcoholic solution and mixed. The resultant solution is then added to an alkaline solvent, e.g. ammoniac alcohol, capable of dissolving both organic compounds, but incapable of dissolving the reaction product, to hydrolyze both organic compounds. Thus, the aimed fine particulate inorganic oxide, having 0.1-10mum particle diameter, &lt;=1.30 standard deviation value of the particle diameter distribution and &gt;= 100m&lt;2&gt;/g specific surface, consisting of silica containing 20mol% or less above- mentioned metallic oxide, and usable widely as a dental filler, etc. is obtained.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a sheet with a pleasant texture, that does not peel off, that does not allow clogging when wiping off and applying makeup, and that has a good appearance, and a sheet-like makeup material using such a sheet.  &lt;P&gt;SOLUTION: Sheets 11, 12, 13 contain 60% or more by mass of hydrophilic fiber on the surface which comes into contact with the skin and are provided with at least a nonwoven cloth on the surface which comes into contact with the skin with 0.1 to 10 mm&lt;SP&gt;2&lt;/SP&gt;of perforated area. At least one part of such sheets is bonded by thermocompression. The nonwoven cloth on the surface which comes into contact with the skin contains inside the surface which comes into contact with the skin a mixture fiber layer 3 composed of a hydrophilic fiber layer 1 and a hydrophobic fiber layer 2. It is desirable that the nonwoven cloth on the surface which comes into contact with the skin contains in the overall nonwoven cloth on the surface which comes into contact with the skin with 30% or more by mass of hydrophilic fiber or is provided with the nonwoven cloth that contains underneath the surface which comes into contact with the skin of the nonwoven cloth on the surface which comes into contact with the skin with either hot-melting fiber or nonwoven cloth that contains hot-melting fiber. A sheet-like makeup material is composed of such sheet to which a liquid composition is applied.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a neurocyte new formation-promoting composition which is high in safety and can easily continuously be taken, and to provide a food or drink compounded with the composition.  &lt;P&gt;SOLUTION: This neurocyte new formation-promoting composition contains theanine as an active ingredient. Concretely, the neurocyte new formation-promoting composition is characterized by containing theanine as an active ingredient to reinforce an ability for differentiating into neurocytes. The neurocyte new formation-promoting composition is characterized by containing theanine as an active ingredient to inhibit ability for differentiating into astroglia cells. The neurocyte new formation-promoting composition is characterized by containing theanine as an active ingredient to improve ability for proliferating nervous system precursor cells. And the food or drink is characterized by containing the neurocyte new formation-promoting composition.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a stable calcium salt of statin in a reduced steps easily reproducible and allowing a large-scale production.  &lt;P&gt;SOLUTION: Processes for producing a calcium salt of a statin from an ester derivative or protected ester derivative of the statin by using calcium hydroxide are provided. The ester or protected ester derivative is brought into contact with calcium hydroxide to obtain the calcium salt. Preferred statins are rosuvastatin, pitavastatin and atorvastatin, simvastatin and lovastatin. In processes beginning with a protected statin-ester derivative, the protecting group is hydrolyzed during salt formation by contact with calcium hydroxide, or is brought into contact with an acid catalyst followed by contact with calcium hydroxide.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
PROBLEM TO BE SOLVED: To form a uniform coating film of small film thickness having a very similar shape to that of the surface of particles to be coated, by using a spray nozzle having such a property that the frequency distribution of liquid drops having diameters of a specified multiple or more of the Sauter average particle size is a specified value or low to the all liquid drops. SOLUTION: When particulate substances are to be coated by using a spray nozzle, such a spray nozzle is used that the frequency distribution of liquid drops having diameters twice or larger as the Sauter average diameter is &lt;=15 wt.% to the all liquid drops. If the frequency distribution exceeds this value, the purpose to uniformly coat particles with a thin film is not realized. Moreover, deposition amount of a resin on a device increases. The proportion is preferably &lt;=5 wt.%, and more preferably &lt;=1 wt.%. The kinds of the spray nozzle are not limited, and a flat spray nozzle, solid spray nozzle or the like can be used. The particulate material is not limited, and preferably it contains a fertilizer as the main component.
The invention relates to a novel ice bag for bone fracture emergency treatment. The novel ice bag for bone fracture emergency treatment comprises an inner bag body and an outer bag body. A main containing cavity is formed in the inner bag body. An annular interlayer cavity is formed between the inner bag body and the outer bag body. The main containing cavity is filled with a mixed solution. The interlayer cavity is filled with compound traditional Chinese medicine. The mixed solution is prepared from, by weight, 20 parts of deionized water, 15 parts of glycerinum and 2 parts of a methylrosanilinium chloride solution. The compound traditional Chinese medicine is prepared from, by weight, 15 parts of sambucus chinensis, 8 parts of the dried body of ground beetle, 8 parts of dragon&#39;s blood, 5 parts of fructus aurantii, 5 parts of drynaria rhizome, 3 parts of neottopteris nidus, 3 parts of teasel roots and 1 part of a honey-fried licorice root. By means of ingenious design of the structure and the optimized matching preparation of content, the novel ice bag has the advantages that fitting is completely tight, and the treatment effect is obvious.
PURPOSE:To improve the absorptivity and dischargeability of an exuding liquid and the peelability from a wound surface and to allow various kinds of the drugs applied from the outer side of the coating material to arrive at the wound surface by incorporating a high-polymer compd. which has a sol-gel transition temp. in an aq. soln. and exhibits a liquid state reversibly at the temp. lower than this transition temp. CONSTITUTION:This material for coating wound contains the high-polymer compd. in which plural blocks having a cloud point and hydrophilic blocks are bonded to each other and which has the sol-gel transition temp. in the aq. soln. and exhibits the liquid state reversibly at the temp. lower than this transition temp. The sol-gel transition temp. is higher than 0 deg.C and &lt;=40 deg.C. The material for coating wound is a compsn. consisting of such high-polymer compd. and an antimicrobial agent. The material contains the high-polymer compd. and the material to promote healing of the wound. These materials are molded to a form of a film, woven fabric, nonwoven fabric, sponge or gel film.
FIELD: virology, veterinary science. SUBSTANCE: invention relates to antigen and immune serum production for neutralization reaction assessment. Strain &#34;ADV&#34; of avian virus of hydropericarditis is deposited in State collection of viruses at N 2330. Virulent strain &#34;ADV&#34; is cultured and titrated in chicken-broilers and in chicken embryo liver culture. Strain induces typical clinical and pathologicoanatomic pattern of disease in 48-72 h after subcutaneous infection and promotes then the formation of virus-neutralizing antibodies. In cultured cells in 72-96 h after infection strain forms typical granulation foci. Activity of immune serum in neutralization reaction is (1:512)-(1:1024). New strain is genetically homogeneous material without any contamination and shows high biological and antigenic activity. EFFECT: new viral strain indicated above, high activity.